Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Tara C. Gangadhar, MD

Tara C. Gangadhar, MD Physician

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Gangadhar is a Penn Medicine employed physician.

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

The comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Patient Comments

Clinical Specialties

Specialty:

  • Medical Oncology

Programs & Centers:

Board Certification:

  • Internal Medicine, 2007
  • Medical Oncology, 2010

Clinical Expertise:

  • Melanoma
  • Skin Cancer

Description of Clinical Expertise

Melanoma
Cutaneous malignancies

Practice Locations and Appointments

  • Abramson Cancer Center

    Perelman Center for Advanced Medicine West Pavilion, 4th Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: New York University School of Medicine
Residency: Indiana University Hospital
Fellowship: University of Chicago Medical Center

Memberships

Abramson Cancer Center of the University of Pennsylvania, National American Society of Clinical Oncology, National American Society of Clinical Pharmacology and Therapeutics, National Melanoma Research Foundation Breakthrough Consortium, National Penn Institute for Immunolology, Local Society for Melanoma Research, International

Hospital Affiliation

Dr. Gangadhar is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

Melanoma
Immune therpay
Targeted therapy
Phase I trials
Combination therapy
Experimental therapeutics
Pharmacology

Selected Publications:

Hodi F Stephen, Hwu Wen-Jen, Kefford Richard, Weber Jeffrey S, Daud Adil, Hamid Omid, Patnaik Amita, Ribas Antoni, Robert Caroline, Gangadhar Tara C, Joshua Anthony M, Hersey Peter, Dronca Roxana, Joseph Richard, Hille Darcy, Xue Dahai, Li Xiaoyun Nicole, Kang S Peter, Ebbinghaus Scot, Perrone Andrea, Wolchok Jedd D: Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34 (13): 1510-7,2016.

Ribas Antoni, Hamid Omid, Daud Adil, Hodi F Stephen, Wolchok Jedd D, Kefford Richard, Joshua Anthony M, Patnaik Amita, Hwu Wen-Jen, Weber Jeffrey S, Gangadhar Tara C, Hersey Peter, Dronca Roxana, Joseph Richard W, Zarour Hassane, Chmielowski Bartosz, Lawrence Donald P, Algazi Alain, Rizvi Naiyer A, Hoffner Brianna, Mateus Christine, Gergich Kevin, Lindia Jill A, Giannotti Maxine, Li Xiaoyun Nicole, Ebbinghaus Scot, Kang S Peter, Robert Caroline: Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA 315 (15): 1600-9,2016.

Shannan Batool, Chen Quan, Watters Andrea, Perego Michela, Krepler Clemens, Thombre Rakhee, Li Ling, Rajan Geena, Peterson Scott, Gimotty Phyllis A, Wilson Melissa, Nathanson Katherine L, Gangadhar Tara C, Schuchter Lynn M, Weeraratna Ashani T, Herlyn Meenhard, Vultur Adina: Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. Pigment cell & melanoma research 29 (3): 317-28,2016.

Dizon Don S, Krilov Lada, Cohen Ezra, Gangadhar Tara, Ganz Patricia A, Hensing Thomas A, Hunger Stephen, Krishnamurthi Smitha S, Lassman Andrew B, Markham Merry Jennifer, Mayer Erica, Neuss Michael, Pal Sumanta Kumar, Richardson Lisa C, Schilsky Richard, Schwartz Gary K, Spriggs David R, Villalona-Calero Miguel Angel, Villani Gina, Masters Gregory: Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34 (9): 987-1011,2016.

Ribas Antoni, Puzanov Igor, Dummer Reinhard, Schadendorf Dirk, Hamid Omid, Robert Caroline, Hodi F Stephen, Schachter Jacob, Pavlick Anna C, Lewis Karl D, Cranmer Lee D, Blank Christian U, O'Day Steven J, Ascierto Paolo A, Salama April K S, Margolin Kim A, Loquai Carmen, Eigentler Thomas K, Gangadhar Tara C, Carlino Matteo S, Agarwala Sanjiv S, Moschos Stergios J, Sosman Jeffrey A, Goldinger Simone M, Shapira-Frommer Ronnie, Gonzalez Rene, Kirkwood John M, Wolchok Jedd D, Eggermont Alexander, Li Xiaoyun Nic: Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet. Oncology 16 (8): 908-18,2015.

Twyman-Saint Victor Christina, Rech Andrew J, Maity Amit, Rengan Ramesh, Pauken Kristen E, Stelekati Erietta, Benci Joseph L, Xu Bihui, Dada Hannah, Odorizzi Pamela M, Herati Ramin S, Mansfield Kathleen D, Patsch Dana, Amaravadi Ravi K, Schuchter Lynn M, Ishwaran Hemant, Mick Rosemarie, Pryma Daniel A, Xu Xiaowei, Feldman Michael D, Gangadhar Tara C, Hahn Stephen M, Wherry E John, Vonderheide Robert H, Minn Andy J: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520 (7547): 373-7,2015.

Gangadhar Tara C, Schuchter Lynn M: Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status. JAMA oncology 1 (4): 427-8,2015.

Wang Tao, Xiao Min, Ge Yingbin, Krepler Clemens, Belser Eric, Lopez-Coral Alfonso, Xu Xiaowei, Zhang Gao, Azuma Rikka, Liu Qin, Liu Rui, Li Ling, Amaravadi Ravi K, Xu Wei, Karakousis Giorgos, Gangadhar Tara C, Schuchter Lynn M, Lieu Melissa, Khare Sanika, Halloran Molly B, Herlyn Meenhard, Kaufman Russel E: BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clinical cancer research : an official journal of the American Association for Cancer Research 21 (7): 1652-64,2015.

Robert Caroline, Ribas Antoni, Wolchok Jedd D, Hodi F Stephen, Hamid Omid, Kefford Richard, Weber Jeffrey S, Joshua Anthony M, Hwu Wen-Jen, Gangadhar Tara C, Patnaik Amita, Dronca Roxana, Zarour Hassane, Joseph Richard W, Boasberg Peter, Chmielowski Bartosz, Mateus Christine, Postow Michael A, Gergich Kevin, Elassaiss-Schaap Jeroen, Li Xiaoyun Nicole, Iannone Robert, Ebbinghaus Scot W, Kang S Peter, Daud Adil: Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384 (9948): 1109-17,2014.

Hamid Omid, Robert Caroline, Daud Adil, Hodi F Stephen, Hwu Wen-Jen, Kefford Richard, Wolchok Jedd D, Hersey Peter, Joseph Richard W, Weber Jeffrey S, Dronca Roxana, Gangadhar Tara C, Patnaik Amita, Zarour Hassane, Joshua Anthony M, Gergich Kevin, Elassaiss-Schaap Jeroen, Algazi Alain, Mateus Christine, Boasberg Peter, Tumeh Paul C, Chmielowski Bartosz, Ebbinghaus Scot W, Li Xiaoyun Nicole, Kang S Peter, Ribas Antoni: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England Journal of Medicine 369 (2): 134-44,2013.

View all publications

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-202
3400 Civic Center Blvd.
South Pavilion, 7th Floor

Philadelphia, PA 19104
Phone: (215) 662-7907
Fax: (215) 662-4646
Patient appointments: 800-789-PENN (7366)